FAS and neoplasm: The increased fraction of Tregs identified in both solid and hematopoietic cancers inhibits anti-tumor immunity by various mechanisms, such as the constitutive expression of CTLA-4, inhibiting CD80/86 co-stimulatory signals on APC (Figure 2) or direct killing of effector T cells via Fas-FasL [86].